Gene · 5892
Papers2,681
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,681
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanism for transmission and pathogenesis of carbapenem-resistant Enterobacterales harboring the carbapenemase IMP and clinical countermeasures. | Microbiol Spectr | 2024 | 38197660 | PubTator, text mining | PubMed |
| Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. | Mol Cancer | 2024 | 38195537 | PubTator, text mining | PubMed |
| A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. | Diagn Pathol | 2024 | 38184614 | PubTator, text mining | PubMed |
| Biology-driven therapy advances in high-grade serous ovarian cancer. | J Clin Invest | 2024 | 38165032 | PubTator, text mining | PubMed |
Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400. | J Med Genet | 2024 | 38123987 | PubTator, text mining | PubMed |
| Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). | ESMO Open | 2024 | 38118367 | PubTator, text mining | PubMed |
| Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement. | Breast | 2024 | 38096711 | PubTator, text mining | PubMed |
| Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction. | Breast | 2024 | 38061307 | PubTator, text mining | PubMed |
| Genetic features of antimicrobial drug-susceptible extraintestinal pathogenic Escherichia coli pandemic sequence type 95. | Microbiol Spectr | 2024 | 38059630 | PubTator, text mining | PubMed |
| Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. | Gynecol Oncol | 2024 | 38041901 | PubTator, text mining | PubMed |
| Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clin Cancer Res | 2024 | 37939124 | PubTator, text mining | PubMed |
| Optical genome mapping reveals balanced and unbalanced genetic changes associated with tumor-forming potential in an early-stage prostate cancer epithelial subline (M2205). | Mol Genet Genomic Med | 2024 | 37902189 | PubTator, text mining | PubMed |
| Mechanism of PARP inhibitor resistance and potential overcoming strategies. | Genes Dis | 2024 | 37588193 | PubTator, text mining | PubMed |
| Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. | J Racial Ethn Health Disparities | 2024 | 36810713 | PubTator, text mining | PubMed |
| [Precision Medicine for Gastric Cancer: Applicability from the Perspective of Helicobacter pylori Infection]. | Korean J Helicobacter Up Gastrointest Res | 2023 | 40502665 | PubTator, text mining | PubMed |
| Securing access to a comprehensive diagnostic panel for children with suspected acute lymphoblastic leukemia: Results from the Mexico in Alliance with St. Jude "Bridge Project". | Front Oncol | 2023 | 38288107 | PubTator, text mining | PubMed |
| Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer. | Curr Oncol | 2023 | 38248100 | PubTator, text mining | PubMed |
| Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. | Int J Mol Sci | 2023 | 38203248 | PubTator, text mining | PubMed |
| The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort. | Cancers (Basel) | 2023 | 38201524 | PubTator, text mining | PubMed |
| Exploiting the DNA Damage Response for Prostate Cancer Therapy. | Cancers (Basel) | 2023 | 38201511 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5892/papers?page=11